Human gene
APP amyloid beta (A4) precursor protein
1 disease group in OMIA reaches this gene, through the animal gene that Ensembl gives as its ortholog. The page shows the chain. It does not say whether an animal is a model of a human disease.
Animal diseases
By each group's best natural-model score, highest first. How the score works.
| OMIA group | Name | Species | Animal gene | Ortholog | The chain reached | Best score |
|---|---|---|---|---|---|---|
| 2538 | Alzheimer disease, APP-related | crab-eating macaque | APP | one to one | Drug |
40.1
|
| 2538 | Alzheimer disease, APP-related | dog | APP | one to one | Drug |
40.1
|
| 2538 | Alzheimer disease, APP-related | pig | APP | one to one | Drug |
40.1
|
| 2538 | Alzheimer disease, APP-related | Rhesus monkey | APP | one to one | Drug |
40.1
|
| 2538 | Alzheimer disease, APP-related | white-tufted-ear marmoset | APP | one to one | Drug |
40.1
|
Target evidence
Each Open Targets association between this gene and a human disease that a disease group reached.
| Human disease | Mondo | Score | Evidence |
|---|---|---|---|
| Alzheimer disease type 1 | MONDO:0007088 | 0.79 | 75 |
| cerebral amyloid angiopathy, APP-related | MONDO:0011583 | 0.75 | 41 |
Drugs
Each ChEMBL drug that acts on this gene.
| Drug | How | Latest stage |
|---|---|---|
| Aducanumab | binding agent | Approved |
| Donanemab | disrupting agent | Approved |
| Lecanemab | inhibitor | Approved |
| Tramiprosate | stabiliser | Approved |
| Bapineuzumab | binding agent | Phase 3 |
| Crenezumab | inhibitor | Phase 3 |
| Gantenerumab | binding agent | Phase 3 |
| Solanezumab | binding agent | Phase 3 |
| Valiltramiprosate | stabiliser | Phase 3 |
| Amilomotide | vaccine antigen | Phase 2/3 |
| Gsk933776 | binding agent | Phase 2 |
| Ponezumab | binding agent | Phase 2 |
| Vanutide Cridificar | vaccine antigen | Phase 2 |
The drug data is ChEMBL's, under CC BY-SA 3.0, and came through Open Targets release 26.09.